HUP0300731A2 - Valzartan-sók, eljárás elżállításukra és az azokat tartalmazó gyógyszerkészítmények - Google Patents

Valzartan-sók, eljárás elżállításukra és az azokat tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0300731A2
HUP0300731A2 HU0300731A HUP0300731A HUP0300731A2 HU P0300731 A2 HUP0300731 A2 HU P0300731A2 HU 0300731 A HU0300731 A HU 0300731A HU P0300731 A HUP0300731 A HU P0300731A HU P0300731 A2 HUP0300731 A2 HU P0300731A2
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
salts
valsartan
valsartan salts
Prior art date
Application number
HU0300731A
Other languages
English (en)
Inventor
Peter Bühlmayer
Wolfgang Marterer
Erwin Marti
Hans Rudolf Oswald
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0300731(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0300731A2 publication Critical patent/HUP0300731A2/hu
Publication of HUP0300731A3 publication Critical patent/HUP0300731A3/hu
Publication of HU229280B1 publication Critical patent/HU229280B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A jelen találmány új valzartansókra vonatkozik, vagy kristályos,részben kristályos és amorf valzartansókra, a megfelelő előállításraés felhasználásra, valamint az ilyen sót tartalmazó gyógyászatikészítményre. Ó
HU0300731A 2000-07-19 2001-07-17 Valsartan salts HU229280B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115556 2000-07-19
PCT/EP2001/008253 WO2002006253A1 (en) 2000-07-19 2001-07-17 Valsartan salts

Publications (3)

Publication Number Publication Date
HUP0300731A2 true HUP0300731A2 (hu) 2003-09-29
HUP0300731A3 HUP0300731A3 (en) 2006-05-29
HU229280B1 HU229280B1 (en) 2013-10-28

Family

ID=8169294

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300731A HU229280B1 (en) 2000-07-19 2001-07-17 Valsartan salts

Country Status (31)

Country Link
US (5) US20030207930A1 (hu)
EP (1) EP1313714B1 (hu)
JP (1) JP4102664B2 (hu)
KR (1) KR100529658B1 (hu)
CN (2) CN100413852C (hu)
AR (2) AR032758A1 (hu)
AT (1) ATE406355T1 (hu)
AU (2) AU2001289672B2 (hu)
BR (1) BR0112665A (hu)
CA (1) CA2415962C (hu)
CY (1) CY1108559T1 (hu)
CZ (1) CZ303389B6 (hu)
DE (1) DE60135560D1 (hu)
DK (1) DK1313714T3 (hu)
EC (1) ECSP034436A (hu)
ES (1) ES2309090T3 (hu)
HK (1) HK1055963A1 (hu)
HU (1) HU229280B1 (hu)
IL (2) IL153882A0 (hu)
MX (1) MXPA03000525A (hu)
MY (2) MY152846A (hu)
NO (1) NO326504B1 (hu)
NZ (1) NZ523557A (hu)
PE (1) PE20020613A1 (hu)
PL (1) PL205715B1 (hu)
PT (1) PT1313714E (hu)
RU (1) RU2275363C2 (hu)
SI (1) SI1313714T1 (hu)
SK (1) SK287558B6 (hu)
WO (1) WO2002006253A1 (hu)
ZA (1) ZA200300285B (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309090T3 (es) 2000-07-19 2008-12-16 Novartis Ag Sales de valsartan.
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
BRPI0306907B8 (pt) * 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
RU2004137109A (ru) * 2002-05-17 2005-10-10 Новартис АГ (CH) Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда
DE60323835D1 (de) * 2002-06-13 2008-11-13 Novartis Ag Calciumsalze von statinen aus indol
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US20040242661A1 (en) 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
WO2004087681A1 (en) * 2003-03-31 2004-10-14 Hetero Drugs Limited A novel amorphous form of valsartan
WO2004094392A1 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
SI2033629T1 (sl) * 2004-12-24 2013-01-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Trden farmacevtski sestavek, ki obsega valsartan
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
WO2007017897A2 (en) * 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
FR2886642B1 (fr) * 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
US20090304797A1 (en) * 2006-06-23 2009-12-10 Tarur Venkatasubramanian Radha Process for the Preparation of Micronized Valsartan
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
JP2010526126A (ja) * 2007-05-07 2010-07-29 シプラ・リミテッド バルサルタンの製造方法
DE602007000211D1 (de) * 2007-06-07 2008-12-11 Inke Sa Verfahren zur Gewinnung eines zur Gewinnung von Valsartan nützlichen Valsartan-Salzes
JP5479346B2 (ja) * 2007-10-05 2014-04-23 ベラステム・インコーポレーテッド ピリミジン置換プリン誘導体
SI3067043T1 (sl) 2007-11-06 2023-04-28 Novartis Ag Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP)
EP2222273A2 (en) 2007-11-12 2010-09-01 Novartis AG Liquid compositions comprising valsartan
KR20130139863A (ko) 2010-08-03 2013-12-23 노파르티스 아게 고도 결정질 발사르탄
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
EP2666773B1 (en) * 2011-01-20 2017-07-26 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
ES2699257T3 (es) 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105541741A (zh) * 2016-01-14 2016-05-04 青岛友诚高新技术有限公司 一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) * 2016-07-29 2016-12-21 陈欣怡 一种缬沙坦的新型固体形式
WO2018040065A1 (zh) * 2016-09-02 2018-03-08 诺瑞特国际药业股份有限公司 缬沙坦二钠盐的晶型
TWI648267B (zh) * 2016-09-02 2019-01-21 諾瑞特國際藥業股份有限公司 纈沙坦二鈉鹽新晶型
BR112019008581A2 (pt) * 2016-10-28 2019-09-17 Biocon Ltd sacubitril valsartana trissódica amorfa e processo para sua preparação
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
EA202090398A1 (ru) 2017-07-28 2020-05-15 Синтон Б.В. Фармацевтическая композиция, включающая сакубитрил и валсартан
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
CN114845713A (zh) * 2019-12-02 2022-08-02 哈曼菲诺化学有限公司 制备高纯度缬沙坦的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499017A (en) * 1983-06-06 1985-02-12 Pfizer Inc. Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
JPH09510225A (ja) 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト バルサルタンを用いる糖尿病性ネフロパシーの治療
MX9707683A (es) 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
BR9611007A (pt) * 1995-10-06 1999-07-13 Novartis Ag Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
ES2309090T3 (es) 2000-07-19 2008-12-16 Novartis Ag Sales de valsartan.

Also Published As

Publication number Publication date
KR100529658B1 (ko) 2005-11-21
JP4102664B2 (ja) 2008-06-18
CN100413852C (zh) 2008-08-27
CA2415962A1 (en) 2002-01-24
MY152846A (en) 2014-11-28
DK1313714T3 (da) 2008-12-15
US8278339B2 (en) 2012-10-02
CY1108559T1 (el) 2014-04-09
HUP0300731A3 (en) 2006-05-29
CZ303389B6 (cs) 2012-08-29
CZ2003117A3 (cs) 2003-05-14
NO20030232D0 (no) 2003-01-17
US9499499B2 (en) 2016-11-22
CN1216873C (zh) 2005-08-31
EP1313714A1 (en) 2003-05-28
US20140073677A1 (en) 2014-03-13
MXPA03000525A (es) 2003-05-14
PL360737A1 (en) 2004-09-20
NO326504B1 (no) 2008-12-15
PE20020613A1 (es) 2002-08-07
US20120329844A1 (en) 2012-12-27
ECSP034436A (es) 2003-03-10
RU2275363C2 (ru) 2006-04-27
CN1443176A (zh) 2003-09-17
ES2309090T3 (es) 2008-12-16
WO2002006253A1 (en) 2002-01-24
EP1313714B1 (en) 2008-08-27
US20080293791A1 (en) 2008-11-27
SK287558B6 (sk) 2011-02-04
NO20030232L (no) 2003-01-17
US20070149587A1 (en) 2007-06-28
ATE406355T1 (de) 2008-09-15
SK552003A3 (en) 2003-07-01
BR0112665A (pt) 2003-06-24
AR032758A1 (es) 2003-11-26
MY136446A (en) 2008-10-31
AU8967201A (en) 2002-01-30
IL153882A (en) 2009-09-01
CN1680341A (zh) 2005-10-12
AU2001289672B2 (en) 2005-12-08
JP2004504307A (ja) 2004-02-12
SI1313714T1 (sl) 2009-02-28
CA2415962C (en) 2010-07-06
NZ523557A (en) 2004-12-24
HU229280B1 (en) 2013-10-28
US20030207930A1 (en) 2003-11-06
IL153882A0 (en) 2003-07-31
DE60135560D1 (de) 2008-10-09
PL205715B1 (pl) 2010-05-31
KR20030015888A (ko) 2003-02-25
AR069374A2 (es) 2010-01-20
HK1055963A1 (en) 2004-01-30
ZA200300285B (en) 2004-03-25
PT1313714E (pt) 2008-11-03

Similar Documents

Publication Publication Date Title
HUP0300731A2 (hu) Valzartan-sók, eljárás elżállításukra és az azokat tartalmazó gyógyszerkészítmények
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CY1111313T1 (el) Σταθερο κρυσταλλικο αλας του 5-μεθυλο-(6s)-τετραϋδροφολικου οξεος
BR0307442A (pt) Sais de valsartana
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
BG66094B1 (bg) Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства
DE602004013405D1 (de) Polymorphe formen von valsartan
TW200420541A (en) Crystalline forms
HUP0300701A2 (hu) Zolpidem hemitartarát, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
HU0102813D0 (en) New betha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it
DE69932620D1 (de) Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0402391A3 (en) Crystalline sodium salt of telmisartan, process for its production and pharmaceutical compositions containing it
AU2003202719A1 (en) Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
HUP0301862A2 (hu) Laktámvegyület, a vegyületet tartalmazó gyógyászati készítmény, eljárás elżállítására, köztitermékek és alkalmazása gyógyászati készítmény elżállítására
HRP20060079A2 (en) Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
DE60131416D1 (de) Chirale fluorochinolizinon arginine salze
AP2002002679A0 (en) Novel polymorph V of torasemide.
MXPA02009210A (es) Modificacion amorfa de torasemida.
MX2009006673A (es) Sales farmaceuticamente aceptables de timodepresion y procedimientos para su fabricacion.
YU81502A (sh) Ciklopostini, postupak za njihovu proizvodnju i njihova primena
MY131231A (en) Pharmaceutical salts of reboxetine

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees